EFFICACY OF IVABRADINE (CORAXAN) IN PATIENTS WITH POST-COVID TACHYCARDIA

EFFICACY OF IVABRADINE (CORAXAN) IN PATIENTS WITH POST-COVID TACHYCARDIA

Authors

  • MAYA KOSTAVA

DOI:

https://doi.org/10.52340/jecm.2022.06.018

Keywords:

Ivabradine, coraxan, post-covid, tachycardia

Abstract

The coronavirus pandemic showed not only an increase in levels of excess morbidity and mortality in the acute phase of an infection, but also the presence of persisting symptoms four weeks after the onset of the disease. A review of the international studies on the prevalence and diversity of the manifestation of the post-covid syndrome is presented. The data on such manifestations of post-covid syndrome as postural orthostatic tachycardia syndrome is being accumulated.In the trial, there were observed 27 patients with post-covid postural orthostatic tachycardia syndrome. All of them were treated by Ivabradine (Coraxan) in dose of 5 mg twice a day per os - during 8 weeks. The results of Holter monitoring in these patients showed a significant decrease of heart rate during the treatment with Coraxan. Functional indicators of the left ventricle contractility (such as EF, EDV and ESV) also were improved. There were revealed clinical improvements including the reduction of heart palpitation, increase of the quality of life and perfection of mood.The author puts forward the future prospects of using Ivabradine (Coraxan) in treatment of post-covid postural orthostatic tachycardia on the basis of literature data and her own clinical experience.

Downloads

Download data is not yet available.

References

Chopza V. Flanders SA, O’Malleg M. et all. Sixty days outcomes among patients hospitalized with Covid-19. Ann. Intern. Med. 2020, M20, 5661 DOI 10, 7326/M20-5661.

Corti A, Bernabei R. Landri F. et all. Persistent Symptoms in patients after acute Covid-19. Jam. Med Assoc 2020, 324-603-5, DOI: 10, 1001/J Am. 2020, 12603.

WHO. Emergency use codes Covid-19 disease outbreak, Available from: https//www.who int/standards/classification of diseases/emergency-use icd codes for Covid-19-disease-outbreak.

Nalbandian A., Sehgal K., Gupta A. et all. Post-acute Covid-19 syndrome. Nat, Med, 2021 Mor. 22 DOI: 101038/s41591-021-01283-2.

M. Stahlberg et all. Post-Covid-19 Tachycardia Syndrome: A phenotype of Post-acute Covid-19 Syndrome. The American Journal of medicine (2021), 7 DOI: https//doiorg/10.1016/j, amjemed (2021), 07.004. https://www.amjemed.com/article/S0002-9343(21) 00472-1/fultext)

Coldstein DS. The possible association between Covid-19 and postural tachycardia syndrome. Heart Rhythm 2020, 18(4); 508-9 DOI: 10,1016/j.hrth.2020-12.07.

Tauch PR, Zadovitian A. Lo HC, et al. Jvabradine in Patients with Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. J.AmCardiol. 2021, 77(7); 861-71, DOI10,1016 j. jacc 202012. 029.

Downloads

Published

2022-09-06

How to Cite

KOSTAVA, M. . (2022). EFFICACY OF IVABRADINE (CORAXAN) IN PATIENTS WITH POST-COVID TACHYCARDIA. Experimental and Clinical Medicine Georgia, (6). https://doi.org/10.52340/jecm.2022.06.018

Issue

Section

Articles

Similar Articles

You may also start an advanced similarity search for this article.

Loading...